<div id="readability-page-1"><div>Overview<ul><li>Cibus Q3 revenue misses analyst expectations, reporting $615,000 compared to $1.39 mln estimate</li><li>Net loss for Q3 was $24.3 mln, significantly lower than $201.5 mln last year</li><li>Company focuses on strategic partnerships and cost reductions to support future growth</li></ul>Outlook<ul><li>Cibus targets initial commercial launch of rice traits in Latin America by 2027</li><li>Company plans commercial expansion of Sustainable Ingredients program in 2026</li><li>Cibus aims to reduce annual net cash usage to $30 mln by 2026</li></ul>Result Drivers<ul><li>LATAM EXPANSION - Cibus continues to progress with herbicide tolerance traits in Rice, targeting initial commercial launches in Latin America by 2027</li><li>INDIA MARKET ENTRY - Cibus engaged AgVayā to support entry into Indian market for advanced gene editing solutions</li><li>BIOFRAGRANCE PILOT - Successfully completed pre-commercial pilot runs for biofragrance products, targeting commercial expansion in 2026</li></ul>Key Details<div><table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q3 Revenue</td><td>Miss</td><td>$615,000</td><td>$1.39 mln (3 Analysts)</td></tr><tr><td>Q3 EPS</td><td></td><td>-$0.44</td><td></td></tr><tr><td>Q3 Net Income</td><td></td><td>-$24.30 mln</td><td></td></tr><tr><td>Q3 Income from Operations</td><td></td><td>-$15.44 mln</td><td></td></tr><tr><td>Q3 Operating Expenses</td><td></td><td>$16.05 mln</td><td></td></tr><tr><td>Q3 Pretax Profit</td><td></td><td>-$24.31 mln</td><td></td></tr></tbody></table></div>Analyst Coverage<ul><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 3 &#34;strong buy&#34; or &#34;buy&#34;, 1 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell&#34;</li><li>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is &#34;buy&#34;</li><li>Wall Street's median 12-month price target for Cibus Inc is $15.50, about 91.3% above its November 12 closing price of $1.35</li></ul>Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</div></div>

CBUS

Cibus reported Q3 revenue of $615,000, missing the $1.39 million estimate, with a net loss of $24.3 million. The company plans strategic partnerships and cost reductions for growth, targeting rice trait launches in Latin America by 2027 and expanding its Sustainable Ingredients program by 2026. Analysts rate Cibus shares as "buy," with a median price target of $15.50, significantly above the current price.

Gene editing firm Cibus misses Q3 revenue estimates